文献速递免疫规划

抗体介导递送T细胞表位至抗原提呈细胞可诱导强CD4与CD8 T细胞应答

Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses.
PubMed 文献 · Vaccine · 2021-02-19

该研究在同一系统中比较两种抗体-抗原融合方式诱导T细胞应答的能力:以T细胞表位替换免疫球蛋白恒定区环(Troybody),或将T细胞表位或完整抗原融合至抗体C端。结果显示两种方式均实现表位提呈,但Troybody在体外及小鼠静脉注射后诱导CD4 T细胞增殖与细胞因子分泌所需浓度比C端融合抗体低10-100倍;以MHCI限制性表位替换该环后,抗体可在体内高效交叉提呈给CD8 T细胞。

要点

  • Troybody型抗体-抗原融合诱导CD4 T细胞应答的效率高于C端融合抗体。
  • Troybody在体外和小鼠体内均于低10-100倍浓度下即可诱导CD4 T细胞增殖与细胞因子分泌。
  • 将MHCI限制性表位替换入恒定区环可实现体内向CD8 T细胞的高效交叉提呈。

核心结论

  • 抗体介导将抗原靶向抗原提呈细胞是增强CD4和CD8肽特异性T细胞激活的有吸引力疫苗策略。

研究设计与样本

  • 研究在体外及小鼠静脉注射后,于同一系统中比较Troybody与C端融合两种抗体-抗原融合模式的T细胞应答诱导能力。

主要发现

  • 两种抗体-抗原融合方式均导致T细胞表位提呈。
  • 最有效的Troybody在体外及小鼠静脉注射后,诱导CD4 T细胞增殖和细胞因子分泌的浓度比C端携带抗原融合的抗体低10-100倍。
  • 以MHCI限制性T细胞表位替换该环后,所得抗体可在体内实现向CD8 T细胞的高效交叉提呈。

临床怎么用

  • 提示抗体-抗原融合靶向APC可作为增强CD4与CD8 T细胞应答的疫苗设计思路,尚处实验研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted delivery of antigen to antigen-presenting cells (APCs) enhances antigen presentation and thus, is a potent strategy for making more efficacious vaccines. This can be achieved by use of antibodies with specificity for endocytic surface molecules expressed on the APC. We aimed to compare two different antibody-antigen fusion modes in their ability to induce T-cell responses; first, exchange of immunoglobulin (Ig) constant domain loops with a T-cell epitope (Troybody), and second, fusion of T-cell epitope or whole antigen to the antibody C-terminus. Although both strategies are well-established, they have not previously been compared using the same system. We found that both antibody-antigen fusion modes led to presentation of the T-cell epitope. The strength of the T-cell responses varied, however, with the most efficient Troybody inducing CD4 T-cell proliferation and cytokine secretion at 10-100-fold lower concentration than the antibodies carrying antigen fused to the C-terminus, both in vitro and after intravenous injection in mice. Furthermore, we exchanged this loop with an MHCI-restricted T-cell epitope, and the resulting antibody enabled efficient cross-presentation to CD8 T cells in vivo. Targeting of antigen to APCs by use of such antibody-antigen fusions is thus an attractive vaccination strategy for increased activation of both CD4 and CD8 peptide-specific T cells.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Høydahl LS, Frigstad T, Rasmussen IB, et al. Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses. Vaccine. 2021. PMID: 33612340. doi:10.1016/j.vaccine.2021.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。